NASDAQ, EDAP - Edap Tms Sa ADR
We develop and market the Ablatherm?, an advanced choice for High Intensity
Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment
is shown to be a minimally invasive and effective treatment option for localized
prostate cancer with a low occurrence of side effects. Ablatherm-HIFU is
generally recommended for patients with localized prostate cancer (stages T1-T2)
who are not candidates for surgery or who prefer an alternative option. It is
also used for patients who failed a radiotherapy treatment. In addition, we are
developing HIFU technology for the treatment of certain other types of tumors.
We also produce and commercialize medical equipment for treatment of urinary
tract stones using Extra-corporeal Shockwave Lithotripsy (?ESWL?). ...
Read SEC Filing on NASDAQ.com »